Ezra Cohen to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Ezra Cohen has written about Randomized Controlled Trials as Topic.
Connection Strength
0.340
-
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678.
Score: 0.153
-
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65.
Score: 0.052
-
The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
Score: 0.045
-
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021 03; 156:281-293.
Score: 0.036
-
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021 03; 34(3):532-541.
Score: 0.035
-
The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7.
Score: 0.020